Systemic lupus erythematosus – an update
Identifieur interne : 001483 ( Main/Exploration ); précédent : 001482; suivant : 001484Systemic lupus erythematosus – an update
Auteurs :Source :
- Drug and Therapeutics Bulletin [ 0012-6543 ] ; 2011-07.
English descriptors
- Teeft :
- Active disease, Adverse events, American college, Antimalarial, Antiphospholipid, Antiphospholipid antibodies, Antiphospholipid syndrome, Arthritis rheum, Belimumab, Bilag indices, Cell aplasia, Clinical features, Corticosteroid, Disease activity, Disease flares, Erythematosus, European league, Global index, High risk, Hydroxychloroquine, Immunosuppressive, Immunosuppressive drugs, Immunosuppressive therapy, Immunosuppressive therapy corticosteroids, Independent risk factor, Irreversible organ damage, Lupus, Lupus anticoagulant, Lupus erythematosus, Lupus nephritis, Lupus patients, Major organ involvement, Mofetil, Mortality rate, Mycophenolate, Mycophenolate mofetil, Observational studies, Pharmaceutical press, Pregnancy loss, Response rate, Rheum, Rituximab, Royal college, Systematic review, Systemic, Systemic lupus erythematosus, Thrombosis, Weight loss.
Abstract
Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disease with a relapsing and remitting course.1 In the UK, the prevalence has been estimated as 25 per 100,000, and the annual incidence as 5.3 for females and 0.7 for males per 100,000.2 Mortality rates for people with SLE have improved over the years. Here we update our 1996 review3 on the management of SLE and discuss recent developments, including the use of biological agents.
Url:
DOI: 10.1136/dtb.2011.02.0044
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000382
- to stream Istex, to step Curation: 000382
- to stream Istex, to step Checkpoint: 000459
- to stream Main, to step Merge: 001485
- to stream Main, to step Curation: 001483
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Systemic lupus erythematosus – an update</title></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:708FD1AF50EEAFEBA69F26F08967FCE925AD256B</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1136/dtb.2011.02.0044</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-L7CKQ38R-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000382</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000382</idno><idno type="wicri:Area/Istex/Curation">000382</idno><idno type="wicri:Area/Istex/Checkpoint">000459</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000459</idno><idno type="wicri:Area/Main/Merge">001485</idno><idno type="wicri:Area/Main/Curation">001483</idno><idno type="wicri:Area/Main/Exploration">001483</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Systemic lupus erythematosus – an update</title></analytic><monogr></monogr><series><title level="j">Drug and Therapeutics Bulletin</title><title level="j" type="abbrev">DTB</title><idno type="ISSN">0012-6543</idno><idno type="eISSN">1755-5248</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2011-07">2011-07</date><biblScope unit="volume">49</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="81">81</biblScope></imprint><idno type="ISSN">0012-6543</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0012-6543</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Active disease</term><term>Adverse events</term><term>American college</term><term>Antimalarial</term><term>Antiphospholipid</term><term>Antiphospholipid antibodies</term><term>Antiphospholipid syndrome</term><term>Arthritis rheum</term><term>Belimumab</term><term>Bilag indices</term><term>Cell aplasia</term><term>Clinical features</term><term>Corticosteroid</term><term>Disease activity</term><term>Disease flares</term><term>Erythematosus</term><term>European league</term><term>Global index</term><term>High risk</term><term>Hydroxychloroquine</term><term>Immunosuppressive</term><term>Immunosuppressive drugs</term><term>Immunosuppressive therapy</term><term>Immunosuppressive therapy corticosteroids</term><term>Independent risk factor</term><term>Irreversible organ damage</term><term>Lupus</term><term>Lupus anticoagulant</term><term>Lupus erythematosus</term><term>Lupus nephritis</term><term>Lupus patients</term><term>Major organ involvement</term><term>Mofetil</term><term>Mortality rate</term><term>Mycophenolate</term><term>Mycophenolate mofetil</term><term>Observational studies</term><term>Pharmaceutical press</term><term>Pregnancy loss</term><term>Response rate</term><term>Rheum</term><term>Rituximab</term><term>Royal college</term><term>Systematic review</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Thrombosis</term><term>Weight loss</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disease with a relapsing and remitting course.1 In the UK, the prevalence has been estimated as 25 per 100,000, and the annual incidence as 5.3 for females and 0.7 for males per 100,000.2 Mortality rates for people with SLE have improved over the years. Here we update our 1996 review3 on the management of SLE and discuss recent developments, including the use of biological agents.</div></front></TEI><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001483 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001483 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:708FD1AF50EEAFEBA69F26F08967FCE925AD256B
|texte= Systemic lupus erythematosus – an update
}}
| This area was generated with Dilib version V0.6.33. |  |